Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06446531 · ClinicalTrials.gov registry record · Phase 1
Prevention of Progression of Prediabetes, Obesity and CV Risk
A Phase 1 study of Cardiovascular Diseases and PreDiabetes, sponsored by The University of Texas Health Science Center at San Antonio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT06446531: Recruiting Phase 1 study of Cardiovascular Diseases and PreDiabetes, sponsored by The University of Texas Health Science Center at San Antonio.
NCT06446531 is a Phase 1 study of Cardiovascular Diseases and PreDiabetes that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 64 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06446531, a Phase 1 study of Cardiovascular Diseases and PreDiabetes, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight. The investigators also want to reduce participants risk of heart problems. The study team will look at how these treatments affect metabolism and other body functions to help find new ways to treat diabetes and obesity in the future.
Primary Outcome
Percentage of glycated hemoglobin level in blood
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG Rybelsus Tablet
- DRUG Jardiance 25Mg Tablet
- DRUG Actos
Study Locations (1)
Texas
- University of Texas Health Science Center at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2024-09-11 |
| Est. Completion | 2027-07 |
| Phase | Phase 1 |
What NCT06446531 shows while recruiting
NCT06446531 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT06446531 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06446531 about?
NCT06446531 is a clinical study titled "Prevention of Progression of Prediabetes, Obesity and CV Risk". The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight. The investigators also want to reduce participants risk of heart problems. The st...
What is the current status of trial NCT06446531?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2024-09-11. Estimated completion is 2027-07.
What conditions does trial NCT06446531 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, PreDiabetes, Weight, Body.
What interventions are being tested in trial NCT06446531?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), Rybelsus Tablet (DRUG), Jardiance 25Mg Tablet (DRUG), Actos (DRUG).
Who is sponsoring clinical trial NCT06446531?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06446531 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06446531's enrollment target sits among peer trials
64 221st of 300 higher than 80 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
RECRUITING · Phase 1
-
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
RECRUITING · Phase 1
-
AB-1002 in Patients With Class III Heart Failure
ACTIVE NOT RECRUITING · Phase 1
-
Effects of NT-0796 in Obese Participants at Risk of Cardiovascular Disease
COMPLETED · Phase 1
-
MRI-Guided Balloon Angioplasty to Treat Blood Flow Blockage in the Legs
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI